Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 235,787,185 papers from all fields of science
Search
Sign In
Create Free Account
Targeted Accrual
Known as:
Protocol Targeted Accrual
, Study Targeted Accrual
, Study Target Accrual
Expand
The final sample size that must be attained according to the study protocol.
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early…
E. Mayer
,
A. Demichele
,
+18 authors
M. Gnant
2016
Corpus ID: 77234760
Background: Cell cycle inhibition is a target of interest for novel cancer therapeutics. Palbociclib (P) is an orally active…
Expand
2015
2015
Abstract OT3-2-06: NEOPAL: A randomized phase II study comparing RCB response to neoadjuvant chemotherapy or letrozole-palbociclib in PAM50 defined postmenopausal luminal breast cancer
P. Cottu
,
F. Duhoux
,
+4 authors
S. Delaloge
2015
Corpus ID: 70842514
Background: HR-positive BC heterogeneously sensitive to neoadjuvant chemotherapy (NEC), with pCR rates varying from 2 to 20% at…
Expand
2014
2014
Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer
H. Hochster
,
N. Uboha
,
+8 authors
H. Lenz
Cancer Chemotherapy and Pharmacology
2014
Corpus ID: 12957250
2013
2013
Abstract P4-01-14: Two-week change in optical tomography predicts residual cancer burden score in women treated with neoadjuvant chemotherapy
E. Lim
,
Jacqueline E. Gunther
,
+12 authors
D. Hershman
2013
Corpus ID: 72113176
Background: A low Residual Cancer Burden (RCB) score after neoadjuvant chemotherapy (NACT) predicts an improved survival in…
Expand
2011
2011
Clinical Trial Development as a Predictor of Accrual Performance—Letter
A. Schroen
Clinical Cancer Research
2011
Corpus ID: 40791775
In the November 15, 2010 edition of Clinical Cancer Research , Cheng and colleagues describe an important finding, namely, the…
Expand
2010
2010
Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.
N. Fowler
,
P. Mclaughlin
,
+7 authors
F. Samaniego
2010
Corpus ID: 74201242
8036 Background: The optimal treatment for newly diagnosed indolent non-Hodgkins lymphoma (NHL) has not been determined. While…
Expand
2010
2010
FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo…
A. Falcone
,
F. Loupakis
,
+7 authors
G. Masi
2010
Corpus ID: 57604893
3543 Background: The combination of BV with cytotoxic drugs is an efficacious strategy in the treatment of mCRC. The triple drug…
Expand
2010
2010
Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM).
S. Jagannath
,
D. Siegel
,
+7 authors
K. Anderson
2010
Corpus ID: 78174569
8133^ Background: Preclinical data show combined histone deacetylase (HDAC) and proteasome inhibition may have synergistic…
Expand
2009
2009
Enhanced Utility Accrual Scheduling Algorithms for Adaptive Real Time System
Idawaty Ahmad
,
Muhammad Fauzan Othman
2009
Corpus ID: 14694722
Problem statement: This study proposed two utility accrual real time scheduling algorithms named as Preemptive Utility Accrual…
Expand
2008
2008
Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy
T. Dragovich
,
D. Laheru
,
+7 authors
M. Hidalgo
2008
Corpus ID: 76822245
4615 Background: Adenocarcinomas of the pancreas overexpress VEGF and PDGF receptors, both targeted by vatalinib, a small…
Expand